IP Library Granted Patent US 9,074,233
Granted Patent B2
US 9,074,233 · App. 13/819,985 · Granted Jul 7, 2015

Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation

Inventors: Ramanaiah C. Kanamarlapudi (Bridgewater, NJ); Steven A. Weissman (Short Hills, NJ); Emerich Eisenreich (Claremont, CA); Xuejun Liu (Arcadia, CA)
Assignee: Concert Pharmaceuticals, Inc.
C12P17/182C07B59/002C07D473/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,074,233
App. No.
13/819,985
Granted
Jul 7, 2015
Kind
B2
Abstract

The present invention provides a process for the preparation of enantiomerically enriched, deuterated secondary alcohols of Formula 1-A by employing ketoreductases or carbonyl reductases without reducing deuterium incorporation.

Claims (40)

1. A process for the preparation of a compound of Formula I-A

comprising the step of reacting a compound of Formula II-A:

or a salt thereof, with a hydride source or a deuteride source in the presence of a ketoreductase or carbonyl reductase to form a compound of Formula I-A with an enantiomeric excess of at least 80%, wherein:

the ketoreductase or carbonyl reductase is selected from CRED A131, CRED A801, CRED A901, CRED A251, CRED A271, KRED-119, KRED-137, KRED-148, KRED-169, KRED-174, KRED-NAD 101, KRED-NAD 102, KRED-NAD112, KRED-NAD 126, ES-KRED-121, ES-KRED-128, ES-KRED-130, ES-KRED-142, ES-KRED-175, ES-KRED-169, and ES-KRED-171;

each of R 4 , R 6 and R 7 is independently selected from —CH 3 and —CD 3 ;

each R 5 is hydrogen or deuterium or a combination thereof;

each Z 2 is the same and is hydrogen or deuterium;

each Z 3 is the same and is hydrogen or deuterium;

each Z 4 is the same and is hydrogen or deuterium;

each Z 5 is the same and is hydrogen or deuterium; and

Y is H when a compound of Formula II-A is reacted with a hydride source; or

Y is D when a compound of Formula II-A is reacted with a deuteride source,

wherein either R 7 is —CD 3 or at least one of Z 2 , Z 3 , Z 4 and Z 5 is deuterium, and wherein the amount of deuterium incorporation at each deuterium in R 7 , Z 2 , Z 3 , Z 4 and Z 5 in the compound of Formula I-A is substantially equal to the amount of deuterium incorporation at corresponding deuterium atoms in R 7 , Z 2 , Z 3 , Z 4 and Z 5 in the compound of Formula II-A.

2. The process of claim 1 , wherein each R 7 is —CD 3 .

3. The process of claim 1 , wherein each Z 2 is deuterium.

4. The process of claim 1 , wherein each Z 2 is hydrogen.

5. The process of claim 1 , wherein each R 5 is deuterium.

6. The process of claim 1 , wherein each R 5 is hydrogen.

7. The process of claim 1 , wherein each Z 3 , Z 4 and Z 5 is hydrogen.

8. The process of claim 7 , wherein R 6 is —CH 3 and R 7 is —CD 3 .

9. The process of claim 8 , wherein R 4 is —CH 3 .

10. The process of claim 7 , wherein R 6 is —CD 3 and R 7 is —CD 3 .

11. The process of claim 1 , wherein each Z 3 , Z 4 and Z 5 is deuterium.

12. The process of claim 11 , wherein each R 6 and each R 4 is —CD 3 .

13. The process of claim 1 , wherein:

a. the compound of Formula II-A is selected from any one of the following:

and

b. the compound of Formula I-A is selected from any one of the following:

14. The process of claim 1 , wherein:

the compound of Formula II-A is

and the compound of Formula I-A is

15. The process of claim 14 , further comprising the step of converting Compound 421(S) to Compound 121(S):

16. The process of claim 1 , wherein the hydride source or deuteride source is (i) a cofactor selected from NAD, NADH, NADP and NADPH, (ii) a reducing sugar and (iii) a dehydrogenase that dehydrogenates the reducing sugar.

17. The process of claim 16 , wherein Y is H; and the hydride source is (i) a cofactor selected from NAD, NADH, NADP and NADPH, (ii) glucose and (iii) glucose dehydrogenase.

18. The process of claim 16 , wherein Y is D; and the deuteride source is (i) a cofactor selected from NAD and NADP, (ii) deuterated glucose, and (iii) glucose dehydrogenase.

19. The process of claim 18 , wherein the deuterated glucose is generated from (i) D-glucono-δ-lactone, and (ii) a metal deuteride or a mixed metal deuteride.

20. The process of claim 19 , wherein the metal deuteride or mixed metal deuteride is NaBD 4 .

21. The process of claim 1 , wherein the step of reacting a compound of Formula II-A or a salt thereof with a hydride source or a deuteride source is performed at a pH between 6.0 and 7.5.

22. The process of claim 21 , wherein the pH is between 6.90 and 7.05.

23. The process of claim 1 , wherein the ketoreductase or carbonyl reductase is selected from CRED A131, CRED A251, and KRED-NAD 101.

Assignments (2)
MERGER Recorded Aug 2, 2023
From: CONCERT PHARMACEUTICALS, INC.
To: SUN PHARMACEUTICAL INDUSTRIES, INC.
Reel/Frame 064465/0383 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2013
From: KANAMARLAPUDI, RAMANAIAH C.; WEISSMAN, STEVEN A.; EISENREICH, EMERICH; LIU, XUEJUN
To: CONCERT PHARMACEUTICALS, INC.
Reel/Frame 030769/0407 →
Continuity (3)
Provisional Application 61379187 · Sep 1, 2010
Provisional Application 61379586 · Sep 2, 2010
Related Publication 20130280768A1 · Oct 24, 2013